These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23442594)

  • 21. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
    Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
    Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
    Dong B; Minze LJ; Xue W; Chen W
    Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate cancer immunotherapy: the path forward.
    Madan RA; Gulley JL
    Curr Opin Support Palliat Care; 2017 Sep; 11(3):225-230. PubMed ID: 28644303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
    Higano CS; Schellhammer PF; Small EJ; Burch PA; Nemunaitis J; Yuh L; Provost N; Frohlich MW
    Cancer; 2009 Aug; 115(16):3670-9. PubMed ID: 19536890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks.
    Comiskey MC; Dallos MC; Drake CG
    Curr Oncol Rep; 2018 Aug; 20(9):75. PubMed ID: 30120592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.
    Sonpavde G; Di Lorenzo G; Higano CS; Kantoff PW; Madan R; Shore ND
    Eur Urol; 2012 Apr; 61(4):639-47. PubMed ID: 22036643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
    Patel A; Fong L
    Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches.
    Arlen PM
    Oncology (Williston Park); 2011 Mar; 25(3):261-2. PubMed ID: 21548469
    [No Abstract]   [Full Text] [Related]  

  • 29. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
    Gardner TA; Elzey BD; Hahn NM
    Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.
    Hall SJ; Klotz L; Pantuck AJ; George DJ; Whitmore JB; Frohlich MW; Sims RB
    J Urol; 2011 Sep; 186(3):877-81. PubMed ID: 21788048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of immunotherapy in castration-resistant prostate cancer (CRPC).
    Suárez C; Morales-Barrera R; Ramos V; Núñez I; Valverde C; Planas J; Morote J; Maldonado X; Carles J
    BJU Int; 2014 Mar; 113(3):367-75. PubMed ID: 23650874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in cancer vaccines for immunotherapy of prostate cancer.
    Jin T; Zhou C; Zhao L; Dong X; Zhou F
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jan; 48(1):148-156. PubMed ID: 36935188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current status of immunological therapies for prostate cancer.
    Antonarakis ES; Drake CG
    Curr Opin Urol; 2010 May; 20(3):241-6. PubMed ID: 20179598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarkers for the development of cancer vaccines: current status.
    Copier J; Whelan M; Dalgleish A
    Mol Diagn Ther; 2006; 10(6):337-43. PubMed ID: 17154650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sipuleucel-T: Prototype for development of anti-tumor vaccines.
    Carballido E; Fishman M
    Curr Oncol Rep; 2011 Apr; 13(2):112-9. PubMed ID: 21243538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer vaccines: can they improve survival?
    Dillman RO
    Cancer Biother Radiopharm; 2015 May; 30(4):147-51. PubMed ID: 25747158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy in prostate cancer.
    Sobol I; Thompson RH; Dong H; Krco C; Kwon ED
    Curr Urol Rep; 2015 Jun; 16(6):34. PubMed ID: 25894495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate cancer vaccines.
    Michael A; Relph K; Annels N; Pandha H
    Expert Rev Vaccines; 2013 Mar; 12(3):253-62. PubMed ID: 23496665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer immunotherapy: sipuleucel-T and beyond.
    Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
    Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.